10月24日-10月27日（北京时间），TCT 2023年会将于美国加利福尼亚州旧金山拉开帷幕。其中，最新突破性临床试验（LBCTs）备受期待。LBCTs论坛共设置了三场线下会议，并与国际顶级期刊（《NEJM》,《Lancet》和《JAMA》）联合进行举办。随后，严道医声网也将持续跟踪报道，并邀请专家对一些重磅内容进行解读，日程早知道，其余最新信息邀您持续关注。
Late-Breaking Clinical Trials Session I
北京时间：10月25日 02:00-03:30
1.PARTNER 3 Low-Risk
Five-Year Clinical and Echocardiographic Outcomes from The PARTNER 3 Low-Risk Randomized Trial
PARTNER 3 低风险随机试验的5年临床和超声心动图结果
2.EVOLUT Low Risk
Four-Year Outcomes from the EVOLUT Low Risk Trial
EVOLUT Low Risk试验的4年结果
3.WATCH TAVR
Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial
经导管主动脉瓣置换术时左心耳封堵的安全性和有效性——WATCH TAVR试验
4.ALIGN-AR
ALIGN-AR Trial: Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement in High Risk Patients With Symptomatic Severe Native Aortic Regurgitation
JenaValve Trilogy经导管主动脉瓣置换术系统在严重的症状性单纯主动脉瓣反流高危患者中的初步结局
Late-Breaking Clinical Trials Session II
北京时间：10月26日 02:00-03:30
1.LIFE-BTKN
Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial
Esprit™ BTK 药物洗脱可吸收支架治疗腘下病变的主要结局：LIFE-BTK 随机对照试验
2.AGENT IDE
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Balloon with Conventional Balloon Angioplasty for In-Stent Restenosis
比较AGENT紫杉醇涂层球囊与传统球囊血管成形术治疗支架内再狭窄的关键性多中心随机试验的主要结局
3.T-PASS
Less Than 1-month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy after Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: The T-PASS Randomized Trial
急性冠脉综合征药物洗脱支架植入后在1个月双联抗血小板治疗后替格瑞洛单药治疗的随机试验
4.PICSO-AMI-I
Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The Randomized PICSO-AMI-I Trial
压力控制间歇性冠状动脉窦闭塞 （PiCSO）治疗急性心肌梗死：PICSO-AMI-I 随机对照试验
Late-Breaking Clinical Trials Session III
北京时间：10月27日 02:00-03:30
1.TRISCEND II
A Randomized Trial of Transcatheter Tricuspid Valve Replacement in Patients With Severe Tricuspid Regurgitation: The TRISCEND II Trial
TRISCEND II研究：经导管三尖瓣置换术治疗重度三尖瓣反流患者的随机试验
2.TRILUMINATE
Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation: Results from the Randomized TRILUMINATE Pivotal Trial
TRILUMINATE Pivotal随机试验：重度三尖瓣反流患者经导管三尖瓣修复术vs药物治疗后的生活质量
3.VIVA
Transcatheter versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annuli: A Randomized Clinical Trial (the VIVA Trial)
VIVA随机临床试验：重度主动脉瓣狭窄合并小瓣环患者经导管置换 vs. 外科主动脉瓣置换术
4.CLASP IID
One Year Outcomes from a Randomized Comparison of Transcatheter Edge-to-Edge Repair Systems For Degenerative MR: The CLASP IID Trial and Registry
CLASP IID试验和注册研究：退行性二尖瓣反流经导管缘对缘修复系统随机比较的1年结果